BioStock: Elicera Therapeutics receives partial payment of 0,5 MEur from EIC

Cell and gene therapy company Elicera Therapeutics has received a partial payment of EUR 500,000 from the European Innovation Council (EIC) under its accelerator program. This is the third of four payments within a funding program that will support the continued clinical development of ELC-301 in the phase I/IIa CARMA study.

Read the interview at biostock.se:

Elicera Therapeutics receives partial payment of 0,5 MEur from EIC - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se